Drugmakers, including multinationals, to cut prices in Russia
Up to 10 domestic and leading global drugmakers operating in the Russian market are considering reducing prices for their drugs, and in particular those intended for the treatment of the most serious diseases, including HIV/AIDS, hepatitis C, tuberculosis and some others, reports The Pharma Letter’s local correspondent.
For example, Russian drugmaker Biocad has announced plans to reduce prices for its Algeron (cepeginterferon alfa-2b), which is a drug for the treatment of hepatitis C, by 10%. According to estimates, this will allow the Russian federal budget to save a sum of 327 million roubles ($5.7 million).
At the same time Janssen, the pharmaceutical division of Johnson & Johnson (NYSE: JNJ), proposed to include a new antitumor drug for a limited group of patients in the "7 Nosology" program (a program for state purchases of the most expensive drugs in Russia), and, in exchange, to reduce prices for it.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze